Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin

Journal of Diabetes Science and Technology

Volumn 11, Issue 1, 2017, Pages 148-156

  Heinemann, Lutz ^a   Baughman, Robert ^b   Boss, Anders ^c   Hompesch, Marcus ^d  

^a Management   (Germany)

^b MannKind Corporation   (United States)

^c SANOFI   (France)

^d Profil Institute for Clinical Research   (United States)

Author keywords

inhaled insulins; insulin therapy; pharmacodynamics; pharmacokinetics; prandial insulin

Indexed keywords

EXCIPIENT; FUMARYL DIKETOPIPERAZINE; INSULIN; INSULIN LISPRO; RECOMBINANT HUMAN INSULIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG POTENCY; GLUCOSE INFUSION; GLYCEMIC CONTROL; HUMAN; INHALER; INSULIN BLOOD LEVEL; MAXIMUM PLASMA CONCENTRATION; PARTICLE SIZE; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; DIABETES MELLITUS; HYPERGLYCEMIA; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; DIABETES MELLITUS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 85009279313     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296816658055     Document Type: Review

References (45)

1. Heise T, Pieber TR., Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007; 9: 648-659.
2. Owens DR, Matfin G, Monnier L., Basal insulin analogues in the management of diabetes mellitus: What progress have we made? Diabetes Metab Res Rev. 2014; 30: 104-119.
3. Pettus J, Santos Cavaiola T, Tamborlane WV, Edelman S,. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016; 32: 478-96.
4. Heinemann L, Heise T, Wahl CH, et al. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med. 1996; 3: 625-629.
5. Chen JW, Christiansen JS, Lauritzen T., Limitations to subcutaneous insulin administration in type 1 diabetes. Diabetes Obes Metab. 2003; 5: 223-233.
6. Cavaiola T, Edelman S., Inhaled insulin: a breath of fresh air? A review of inhaled insulin. Clin Ther. 2014; 36: 1275-1289.
7. Home PD., Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes? Diabetes Obes Metab. 2015; 17 (11): 1011-1020.
8. Heinemann L, Muchmore DB., Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol. 2012; 6: 728-742.
9. Bernstein G., Delivery of insulin to the buccal mucosa utilizing the RapidMist system. Expert Opin Drug Deliv. 2008; 5: 1047-1055.
10. Pozzilli P, Raskin P, Parkin CG., Review of clinical trials: update on oral insulin spray formulation. Diabetes Obes Metab. 2010; 12: 91-96.
11. Kapitza C, Zijlstra E, Heinemann L, Castelli MC, Riley G, Heise T., Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetes. Diabetes Care. 2010; 33: 1288-1290.
12. Duan X, Mao S., New strategies to improve the intranasal absorption of insulin. Drug Discov Today. 2010; 15: 416-427.
13. Ochs M, Nyengaard JR, Jung A, et al. The number of alveoli in the human lung. Am J Respir Crit Care Med. 2004; 169: 120-124.
14. Patton JS, Byron PR., Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007; 6: 67-74.
15. Cefalu WT., Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care. 2004; 27: 239-246.
16. Mastrandrea LD,. Inhaled insulin: overview of a novel route of insulin administration. Vasc Health Risk Manag. 2010; 6: 47-58.
17. Rave K, Bott S, Heinemann L, et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care. 2005; 28: 1077-1082.
18. Bailey CJ, Barnett AH., Why is Exubera being withdrawn? BMJ. 2007; 335: 1156.
19. Heinemann L., Current status of the development of inhaled insulin. Br J Diabetes Vasc Dis. 2004; 4: 295-301.
20. Angelo R, Rousseau K, Grant M, Leone-Bay A, Richardson P., Technosphere insulin: defining the role of Technosphere particles at the cellular level. J Diabetes Sci Technol. 2009; 3: 545-554.
21. Raskin P, Heller S, Honka M, et al. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial. Diabetes Obes Metab. 2012; 14: 163-173.
22. Richardson PC, Boss AH., Technosphere insulin technology. Diabetes Technol Ther. 2007; 9 (suppl 1): S65-S72.
23. MannKind Corporation. Afrezza highlights of prescribing information. 2014. Updated 2016. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022472lbl.pdf. Accessed January 29, 2016.
24. Baughman RA, Amin N, Watkins E, Chung P-C, Nezamis JP, Boss AH., A phase 1, open-label, randomized dose proportionality study of Technosphere Insulin Inhalation Powder (TI) doses up to 80 U administered with the Gen2 inhaler in healthy subjects. Diabetes. 2013; 62 (suppl 1):A251 abstract 982-P.
25. Baughman RA, Amin N, Watkins E, Chung PC, Nezamis JP, Boss AH., A phase 1, open-label, randomized dose proportionality study of Technosphere Insulin Inhalation Powder (TI) doses up to 80 U administered with the Gen2 inhaler in healthy subjects. Poster presented at: American Diabetes Association; Chicago, IL; June 21, 2013.
26. FDA Briefing Document. Endocrinologic and Metabolic Drug Advisory Committee. 1, 2014. NDA 022472. AFREZZA (insulin human [rDNA origin]) inhalation powder: an ultra-rapid acting insulin treatment to improve glycemic control in adult patients with diabetes mellitus. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM390865.pdf. Accessed January 29, 2016.
27. Rave K, Heise T, Pfützner A, Boss AH., Coverage of postprandial blood glucose excursions with inhaled technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. Diabetes Care. 2007; 30: 2307-2308.
28. Rave K, Heise T, Heinemann L, Boss AH., Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes. J Diabetes Sci Technol. 2008; 2: 205-212.
29. Rave K, Potocka E, Heinemann L, et al. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab. 2009; 11: 715-720.
30. Cassidy JP, Amin N, Marino M, et al. Insulin lung deposition and clearance following Technosphere insulin inhalation powder administration. Pharm Res. 2011; 28: 2157-2164.
31. Bode BW, McGill JB, Lorber DL, et al. Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care. 2015; 38: 2266-2273.
32. Del Sindaco P, Ciofetta M, Lalli C, et al. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med. 1998; 15: 592-600.
33. Tamás G, Marre M, Astorga R, et al. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. Diabetes Res Clin Pract. 2001; 54: 105-114.
34. Potocka E, Cassidy JP, Haworth P, Heuman D, van Marle S, Baughman RA Jr., Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. J Diabetes Sci Technol. 2010; 4: 1164-1173.
35. Baughman RA, Haworth PC, Litwin JS, McDowell JA, Cassidy JP, Boss AH., No cardiac effects found with therapeutic and supratherapeutic doses of Technosphere inhalation powder: results from a thorough QTc clinical study. Diabetes. 2011; 60 (suppl 1): A255 abstract 933-P.
36. Boss AH, Petrucci R, Lorber D., Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin. J Diabetes Sci Technol. 2012; 6: 773-779.
37. Potocka E, Hovorka R, Baughman RA, et al. AFRESA Suppresses endogenous glucose production earlier than a rapid-acting analog (lispro) and inhaled exubera. Diabetes. 2009; 58 (suppl 1):abstract 232-OR.
38. Cassidy JP, Baughman RA, Schwartz SL, Haworth PC, Boss AH, Richardson PC., AFRESA (Technosphere Insulin) dosage strengths are interchangeable. Diabetes. 2009; 58 (suppl 1):abstract 425-P.
39. Rizza RA, Mandarino LJ, Gerich JE., Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol. 1981; 240: E630-E639.
40. Becker RH, Frick AD., Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet. 2008; 47: 7-20.
41. Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010; 375: 2244-2253.
42. Zisser H, Dassau E, Lee JJ, Harvey RA, Bevier W, Doyle FJ III,. Clinical results of an automated artificial pancreas using technosphere inhaled insulin to mimic first-phase insulin secretion. J Diabetes Sci Technol. 2015; 9: 564-572.
43. Kapsner P, Bergenstal R, Rendell M, et al. Comparative efficacy and safety of technosphere insulin and a rapid-acting analogue both given with glargine in subjects with type 1 diabetes mellitus in a 52-week study. Diabetologia. 2009; 52 (suppl 1): S386.
44. Garg SK, Kelly WC, Freson BJ, Petrucci RE, Ritchie PJ., Treat-to-target Technosphere insulin in patients with type 1 diabetes. Diabetes. 2011; 60 (suppl 1): A257 (941-P).
45. Blonde L, Gill J, Nikonova E, Stewart J, Bode B., Reduced hypoglycemia is observed with inhaled insulin versus subcutaneous insulin aspart in type 1 diabetes mellitus. Late breaking abstract #1220 presented at the American Association of Clinical Endocrinologists 24th Annual Meeting & Clinical Congress, 2015. http://am2015.aace.com/sites/all/files/Late-Breaking.pdf. Accessed January 2016.